secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124576
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio posts Q3 net loss of $162M; acoramidis PDUFA set for Nov 29, 2024
---------------------------------------------------------------------------

- Net loss per share of $0.86; revenue $2.7M vs $4.1M YoY; operating expenses $194.5M.
- Cash, equivalents, and short-term restricted cash $405.7M; expects $500M milestone from acoramidis upon FDA approval.
- FDA accepted acoramidis NDA; PDUFA date November 29, 2024; 42-month OLE data to be presented at AHA.
- FDA granted Breakthrough Therapy Designation to oral infigratinib for achondroplasia.
- Phase 3 FORTIFY trial for LGMD2I/R9 enrollment completed; interim analysis expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/0000950170-24-124576-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024124576/bbio-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124576

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer